{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:39:48Z","timestamp":1779367188101,"version":"3.53.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ejpb.2015.01.012","type":"journal-article","created":{"date-parts":[[2015,1,20]],"date-time":"2015-01-20T14:13:17Z","timestamp":1421763197000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer\u2122 family"],"prefix":"10.1016","volume":"90","author":[{"given":"M.","family":"Hoppentocht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.W.","family":"Akkerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hagedoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.W.","family":"Frijlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2015.01.012_b0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jcf.2009.04.005","article-title":"Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus","volume":"8","author":"Heijerman","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2015.01.012_b0010","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/187152812800392850","article-title":"Inhaled antibiotics for nosocomial pneumonia","volume":"11","author":"Karvouniaris","year":"2012","journal-title":"Inflamm. Allergy-Drug Targets"},{"key":"10.1016\/j.ejpb.2015.01.012_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2013.10.019","article-title":"Developments and strategies for inhaled antibiotic drugs in tuberculosis therapy: a critical evaluation","volume":"86","author":"Hoppentocht","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2015.01.012_b0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1067\/mic.2000.110214","article-title":"Microbiologic contamination study of nebulizers after aerosol therapy in patients with cystic fibrosis","volume":"28","author":"Vassal","year":"2000","journal-title":"Am. J. Infect. Control."},{"key":"10.1016\/j.ejpb.2015.01.012_b0025","first-page":"58","article-title":"The cleaning and disinfection of nebulizers used at home and in a cystic fibrosis centre","volume":"6","author":"Le Brun","year":"2000","journal-title":"Eur. Hosp. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.012_b0030","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ppul.20594","article-title":"Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety","volume":"42","author":"Geller","year":"2007","journal-title":"Pediatr. Pulm."},{"key":"10.1016\/j.ejpb.2015.01.012_b0035","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.ejpb.2015.01.012_b0040","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40261-013-0082-0","article-title":"Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study","volume":"33","author":"Stass","year":"2013","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejpb.2015.01.012_b0045","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1128\/AAC.02346-12","article-title":"Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis","volume":"57","author":"Dharmadhikari","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejpb.2015.01.012_b0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejps.2005.11.013","article-title":"Design and in vitro performance testing of multiple air classifier technology in a new disposable inhaler concept (Twincer\u00ae) for high powder doses","volume":"28","author":"de Boer","year":"2006","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.01.012_b0055","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jcf.2006.10.010","article-title":"Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study","volume":"6","author":"Westerman","year":"2007","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejpb.2015.01.012_b0060","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijpharm.2012.08.020","article-title":"Characterisation of high dose aerosols from dry powder inhalers","volume":"437","author":"Grasmeijer","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.012_b0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1086\/520189","article-title":"A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African Hospital","volume":"29","author":"Sacks","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejpb.2015.01.012_b0070","unstructured":"WHO, Treatment of Tuberculosis Guidelines, 2010."},{"key":"10.1016\/j.ejpb.2015.01.012_b0075","unstructured":"E.A. Nardell, A. Stoltz, A. Dharmadhikari, E. de Kock, M. Mphahlele, M. Hoppentocht, et al., Inhaled colistin: a novel approach for reducing drug-resistant TB transmission, in: S. Poster (Ed.), Int. Union Against Tuberc. Lung Dis., Vancouver, 2013."},{"key":"10.1016\/j.ejpb.2015.01.012_b0080","doi-asserted-by":"crossref","unstructured":"Diagnostic Standards and Classification of Tuberculosis in Adults and Children: This Official Statement of the American Thoracic Society and the Centers for Disease Control and Prevention was Adopted by the ATS Board of Directors, July 1999. This Statement, Am. J. Respir. Crit. Care Med., vol. 161, 2000, pp. 1376\u20131395, http:\/\/dx.doi.org\/10.1164\/ajrccm.161.4.16141.","DOI":"10.1164\/ajrccm.161.4.16141"},{"key":"10.1016\/j.ejpb.2015.01.012_b0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75C","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.01.012_b0090","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejps.2004.06.005","article-title":"The role of particle engineering in relation to formulation and de-agglomeration principle in the development of a dry powder formulation for inhalation of cetrorelix","volume":"23","author":"Zijlstra","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.01.012_b0095","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/jps.21629","article-title":"The role of force control agents in high-dose dry powder inhaler formulations","volume":"98","author":"Begat","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2015.01.012_b0100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ijpharm.2012.01.026","article-title":"Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells","volume":"426","author":"Aquino","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.012_b0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0032-5910(91)80179-M","article-title":"Investigation of applied compression on the adhesion of powders to a substrate surface","volume":"65","author":"Lam","year":"1991","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2015.01.012_b0110","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00166410","article-title":"What the pulmonary specialist should know about the new inhalation therapies","volume":"37","author":"Laube","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejpb.2015.01.012_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2014.08.013","article-title":"Inhaled antimicrobial therapy \u2013 Barriers to effective treatment","author":"Weers","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2015.01.012_b0120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0378-5173(01)00969-3","article-title":"Effect of an external resistance to airflow on the inspiratory flow curve","volume":"234","author":"de Koning","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2015.01.012_b0125","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1378\/chest.124.1.360","article-title":"Inhalation of a dry powder tobramycin PulmoSphere formulation in healthy volunteers","volume":"124","author":"Newhouse","year":"2003","journal-title":"Chest"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115000156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641115000156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,26]],"date-time":"2018-09-26T01:57:12Z","timestamp":1537927032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641115000156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":25,"alternative-id":["S0939641115000156"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.01.012","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Cyclops for pulmonary delivery of aminoglycosides; a new member of the Twincer\u2122 family","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2015.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}